Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
ST. LOUIS, Feb. 08, 2016 -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2015 on Monday, February 22, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2015 financial results conference call | ||||||
| When: | Monday, February 22nd at 4:30 p.m. Eastern Time (1:30 p.m. PT) | ||||||
| Dial In Number: | To access the live call, dial 888-417-8465 (US and Canada) or 719-325-2329 (International) and give the participant pass code 4685179. | ||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com | ||||||
| Call Replay: | A replay of the call will be available approximately one hour following the end of the call through 7:30 p.m. ET on February 29, 2016. | ||||||
| Replay Numbers: | 888-203-1112 (US and Canada) | ||||||
| 719-457-0820 (International) | |||||||
| Replay passcode: 4685179 | |||||||
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
Press Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 [email protected]
